The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen

Drug Delivery

Volumn 16, Issue 4, 2009, Pages 196-204

  Bolhassani, Azam ^a,b   Ghasemi, Nahid ^b   Servis, Catherine ^c   Taghikhani, Mohammad ^b   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Delivery system; DNA vaccination; E7; Human papillomavirus (HPV); Polyethylenimine (PEI); Tat protein

Indexed keywords

DNA VACCINE; DRUG CARRIER; HUMAN PAPILLOMAVIRUS TYPE 16 E7 VACCINE; POLYETHYLENEIMINE 600 TAT PROTEIN CONJUGATE; POLYETHYLENEIMINE DERIVATIVE; POLYMER; UNCLASSIFIED DRUG; WART VIRUS VACCINE; AVIDIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PEI600 AVIDIN; PEI600-AVIDIN; POLYETHYLENEIMINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONJUGATE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; FEMALE; GENE DELIVERY SYSTEM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; ANIMAL; ANTIBODY PRODUCTION; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIBODY FORMATION; AVIDIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; POLYETHYLENEIMINE; TRANSFECTION; VACCINES, DNA;

EID: 70350633739     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540902757721     Document Type: Article

References (38)

1. Dubensky TW, Liu MA, Ulmer JB. (2000). Delivery systems for gene-based vaccines. Molec Med, 6, 723-732
2. Hellgren I, Gorman J, Sylven C. (2004). Factors controlling the efficiency of Tat-mediated plasmid DNA transfer. J Drug Target, 12, 39-47.
3. Jarver P, Langel U. (2004). The use of cell-penetrating peptides as a tool for gene regulation. DDT, 9, 395-402.
4. Zorko M, Langel U. (2005). Cell-penetrating peptides: mechanism and kinetics cargo delivery. Adv Drug Deliv Rev, 57, 529-545
5. Gupta B, Levchenko TS, Torchilin VP. (2005). Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev, 57, 637-651
6. Noguchi H, Matsumoto S. (2006). Protein transduction technology: a novel therapeutic perspective. Acta Med, 60, 1-11.
7. Wagstaff KM, Jans DA. (2006). Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem, 13, 1371-1387
8. Martin ME, Rice KG. (2007). Peptide-guided gene delivery. The AAPS J, 9, E18-29.
9. Brooks H, Lebleu B, Vives E. (2005). Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev, 57, 559-577
10. Tung CH, Mueller S, Weissleder R. (2002). Novel branching membrane translocational peptide as gene delivery vector. Bioorg Med Chem, 10, 3609-3614
11. Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, Orlov SV, Perevozchikov AP. (2003). Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem, 278, 42625-42636
12. Riedl P, Reimann J, Schirmbeck R. (2004). Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines. J Mol Med, 82, 144-152
13. Dizhe EB, Ignatovich IA, Burov SV, Pohvoscheva AV, Akifiev BN, Efremov AM, Perevozchikov AP, Orlov SV. (2006). Complexes of DNA with cationic peptides: conditions of formation and factors effecting internalization by mammalian cells. Biochemistry, 71, 1350-1356
14. Alexis F, Lo SL, Wang S. (2006). Covalent attachment of low molecular weight poly (ethyleneimine) improves Tat peptide mediated gene delivery. Adv Mater, 18, 2174-2178
15. Wang S. (2006). Tat peptide conjugates of low molecular weight polyethylenimine as effective non-viral gene delivery vectors. Molec Ther, 13, S76.
16. Boussif O, Lezoualch F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci, 92, 7297-7301
17. Godbey WT, Wu KK, Mikos AG. (1999). Poly (ethylenimine) and its role in gene delivery. J Contr Rel, 60, 149-160
18. Putnam D, Gentry CA, Pack DW, Langer R. (2001). Polymerbased gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci, 98, 1200-1205
19. Tang GP, Guo HY, Alexis F, Wang X, Zeng S, Lim TM, Ding J, Yang YY, Wang S. (2006). Low molecular weight polyethylenimines linked by d£- cyclodextrin for gene transfer into the nervous system. J Gene Med, 8, 736-744
20. Hausen HZ, Villiers EMD. (1994). Human papillomaviruses. Ann Rev Microbiol, 48, 427-447
21. Schiller J, Davies P. (2004). Delivering on the promise: HPV vaccines and cervical cancer. Nature Rev, 2, 343-347
22. Damania B. (2006). DNA tumor viruses and human cancer. Trends Microbiol, 15, 38-44.
23. Yan Q, Cheung YK, Cheng SC, Xian-Hua W, Yong X. (2007). A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. Gynecol Oncol, 104, 199-206.
24. Bolhassani A, Zahedifard F, Taghikhani M, Rafati S. (2008). Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine, 26, 3362-3370
25. Chen CH, Wang TL, Hung CF, Yang Y, Young R, Pardoll D, Wu TC. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res, 60, 1035-1042
26. Leitner WW, Hammerl P, Thalhamer J. (2001). Nucleic acid for the treatment of cancer: Genetic vaccines and DNA adjuvants. Curr Pharm Des, 7, 1641-1667
27. Doria-Rose NA, Haigwood NL. (2003). DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods, 31, 207-216
28. Lewis J. (2004). Therapeutic cancer vaccines: using unique antigens. PNAS, 101, 14653-14656
29. Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI. (2002). Both E7 and CpG oligodeoxynuclotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res, 62, 7234-7240
30. Michel N, Osen W, Gissmann L, Schumacher TNM, Zentgraf H, Muller M. (2002). Enhanced immunogenicity of HPV16 E7 fusion proteins in DNA vaccination. Virology, 294, 47-59.
31. Giannouli C, Brulet JM, Gesche F, Rappaport J, Burny A, Leo O, Hallez S. (2003). Fusion of a tumor-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res, 23, 3523-3532
32. Li H, Ou X, Xiong J. (2007). Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Gynecol Oncol, 104, 564-571
33. Huang CY, Chen CA, Lee CN, Chang MC, Cheng WF. (2007). DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecol Oncol, 107, 404-412
34. Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, Wu TC. (2008). Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine, 26, 351-360
35. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. (1997). Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol, 159, 1666-1668
36. Riedl P, Buschle M, Reimann J, Schirmbeck R. (2002). Binding immune-stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants. Eur J Immunol, 32, 1709-1716
37. Riedl P, Reimann J, Schirmbeck R. (2004). Complexes of DNA vaccines with cationic, antigenic peptides are potent, polyvalent CD8+ T cell-stimulating immunogens. Methods Molec Med, 127, 159-169
38. Kleemann E, Neu M, Jekel N, Fink L, Schmehl T, Gessler T, Seeger W, Kissel T. (2005). Nano-carriers for DNA delivery to the lung based upon a Tat-derived peptide covalently coupled to PEG-PEI. J Contr Rel, 109, 299-316.